Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma
NCT07069699Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2027
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pidnarulex in Burkitt lymphoma (BL), double-expressor lymphoma (DEL), high grade B-cell lymphoma (HGBCL), sponsored by National Cancer Institute. Planned start Jan 2027; status: recruiting.
02
Drugs
pidnarulex
03
Conditions
Burkitt lymphoma (BL)double-expressor lymphoma (DEL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT07069699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07069699.